PT - JOURNAL ARTICLE AU - Ulrich H. Weidle AU - Daniela Maisel AU - Dirk Eick TI - Synthetic Lethality-based Targets for Discovery of New Cancer Therapeutics DP - 2011 Jul 01 TA - Cancer Genomics - Proteomics PG - 159--171 VI - 8 IP - 4 4099 - http://cgp.iiarjournals.org/content/8/4/159.short 4100 - http://cgp.iiarjournals.org/content/8/4/159.full SO - Cancer Genomics Proteomics2011 Jul 01; 8 AB - Synthetic lethality is based on the incompatibility of cell survival with the loss of function of two or more genes, not with loss of function of a single gene. If targets of synthetic lethality are deregulated or mutated in cancer cells, the strategy of synthetic lethality can result in significant increase of therapeutic efficacy and a favourable therapeutic window. In this review, we discuss synthetic lethality based on deficient DNA repair mechanisms, activating mutations of RAS, loss of function mutations of the tumor suppressor genes p53, Rb and von Hippel-Lindau, and disruption of interactive protein kinase networks in the context of development of new anticancer agents.